The U.S. Food and Drug Administration (FDA), Office of Clinical Pharmacology (OCP) announces the availability of the 2022 OCP Annual Report. OCP is a dynamic, purpose-driven organization dedicated to promoting and protecting global public health through the application of clinical pharmacology and translational medicine principles.
The theme of this year’s report is “Innovation,” demonstrated in every aspect of OCP’s work, including regulatory review, policy development and implementation, research, stakeholder engagement, and program management. This report spotlights the dedication of OCP staff to the mission of FDA and their collaborative efforts toward improving public health by combining state-of-the-art translational science with rigorous regulatory assessment.
The 2022 OCP Annual Report also highlights the Office’s strategic priorities and “Roadmap to 2025”, a plan that will act as a guide in making values-driven decisions that ultimately accelerate the science of clinical pharmacology and translational medicine for the benefit of patients. Learn more about OCP’s diverse functional responsibilities, dedicated and collaborative culture, achievements, and 2023 outlook in the 2022 OCP Annual Report. To access past OCP annual reports and learn more about OCP, visit the OCP webpage.
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
